LOS ANGELES, Jan 7 (Reuters) - Biogen Idec Inc (BIIB.O) has moved a long-acting version of its multiple sclerosis drug, Avonex, into trials designed to meet requirements for regulatory approval, the company’s chief executive said on Wednesday.
CEO Jim Mullen said during an investor conference being held in New York that the company is studying dosing the drug once every two weeks as well as once monthly.
“I think we’ve got a good chance of similar efficacy as interferons,” he said.
Patients in the trials will be treated for one year and full results will likely be available in two years, Mullen added. (Reporting by Deena Beasley; Editing by Andre Grenon)